Platinum-resistant Ovarian Cancer Recruiting Phase 2 Trials for Bevacizumab (DB00112)

Also known as: Platinum drug resistant Ovarian cancer / Platinum-resistant Ovarian Cancer (PROC) / Platinum Resistant Ovarian Cancer

DBCOND0068919 (Platinum-resistant Ovarian Cancer)Recruiting2 IdentifierTitlePurposeDrugs
NCT04787289A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian CancerTreatment
NCT05310344Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian CancerTreatment